🇺🇸 FDA
Patent

US 9518259

Compounds and methods for modulating interaction between proteins and target nucleic acids

granted A61PA61P21/00A61P35/00

Quick answer

US patent 9518259 (Compounds and methods for modulating interaction between proteins and target nucleic acids) held by Ionis Pharmaceuticals, Inc. expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P21/00, A61P35/00